Laura A Bertrand1, Lewis J Thomas1, Peng Li2, Claire M Buchta1, Shannon K Boi3, Rachael M Orlandella3, James A Brown4, Kenneth G Nepple4, Lyse A Norian5. 1. Department of Urology, The University of Iowa Carver College of Medicine, Iowa City, IA. 2. Department of Biostatistics, School of Public Health, The University of Alabama at Birmingham, Birmingham, AL. 3. Graduate Biomedical Sciences, University of Alabama at Birmingham, Birmingham, AL. 4. Department of Urology, The University of Iowa Carver College of Medicine, Iowa City, IA; Holden Comprehensive Cancer Center, The University of Iowa Carver College of Medicine, Iowa City, IA. 5. Department of Nutrition Sciences, The University of Alabama at Birmingham School of Health Professions, Birmingham, AL; Comprehensive Cancer Center, The University of Alabama at Birmingham, Birmingham, AL. Electronic address: lnorian@uab.edu.
Abstract
OBJECTIVES: Obesity, typically defined as a body mass index (BMI)≥30kg/m2, is an established risk factor for renal cell carcinoma (RCC) but is paradoxically linked to less advanced disease at diagnosis and improved outcomes. However, BMI has inherent flaws, and alternate obesity-defining metrics that emphasize abdominal fat are available. We investigated 3 obesity-defining metrics, to better examine the associations of abdominal fat vs. generalized obesity with renal tumor stage, grade, or R.E.N.A.L. nephrometry score. METHODS AND MATERIALS: In a prospective cohort of 99 subjects with renal masses undergoing resection and no evidence of metastatic disease, obesity was assessed using 3 metrics: body mass index (BMI), radiographic waist circumference (WC), and retrorenal fat (RRF) pad distance. R.E.N.A.L. nephrometry scores were calculated based on preoperative CT or MRI. Univariate and multivariate analyses were performed to identify associations between obesity metrics and nephrometry score, tumor grade, and tumor stage. RESULTS: In the 99 subjects, surgery was partial nephrectomy in 51 and radical nephrectomy in 48. Pathology showed benign masses in 11 and RCC in 88 (of which 20 had stage T3 disease). WC was positively correlated with nephrometry score, even after controlling for age, sex, race, and diabetes status (P = 0.02), whereas BMI and RRF were not (P = 0.13, and P = 0.57, respectively). WC in stage T2/T3 subjects was higher than in subjects with benign masses (P = 0.03). In contrast, subjects with Fuhrman grade 1 and 2 tumors had higher BMI (P<0.01) and WC (P = 0.04) than subjects with grade 3 and 4 tumors. CONCLUSIONS: Our data suggest that obesity measured by WC, but not BMI or RRF, is associated with increased renal mass complexity. Tumor Fuhrman grade exhibited a different trend, with both high WC and BMI associated with lower-grade tumors. Our findings indicate that WC and BMI are not interchangeable obesity metrics. Further evaluation of RCC-specific outcomes using WC vs. BMI is warranted to better understand the complex relationship between general vs. abdominal obesity and RCC characteristics.
OBJECTIVES: Obesity, typically defined as a body mass index (BMI)≥30kg/m2, is an established risk factor for renal cell carcinoma (RCC) but is paradoxically linked to less advanced disease at diagnosis and improved outcomes. However, BMI has inherent flaws, and alternate obesity-defining metrics that emphasize abdominal fat are available. We investigated 3 obesity-defining metrics, to better examine the associations of abdominal fat vs. generalized obesity with renal tumor stage, grade, or R.E.N.A.L. nephrometry score. METHODS AND MATERIALS: In a prospective cohort of 99 subjects with renal masses undergoing resection and no evidence of metastatic disease, obesity was assessed using 3 metrics: body mass index (BMI), radiographic waist circumference (WC), and retrorenal fat (RRF) pad distance. R.E.N.A.L. nephrometry scores were calculated based on preoperative CT or MRI. Univariate and multivariate analyses were performed to identify associations between obesity metrics and nephrometry score, tumor grade, and tumor stage. RESULTS: In the 99 subjects, surgery was partial nephrectomy in 51 and radical nephrectomy in 48. Pathology showed benign masses in 11 and RCC in 88 (of which 20 had stage T3 disease). WC was positively correlated with nephrometry score, even after controlling for age, sex, race, and diabetes status (P = 0.02), whereas BMI and RRF were not (P = 0.13, and P = 0.57, respectively). WC in stage T2/T3 subjects was higher than in subjects with benign masses (P = 0.03). In contrast, subjects with Fuhrman grade 1 and 2 tumors had higher BMI (P<0.01) and WC (P = 0.04) than subjects with grade 3 and 4 tumors. CONCLUSIONS: Our data suggest that obesity measured by WC, but not BMI or RRF, is associated with increased renal mass complexity. Tumor Fuhrman grade exhibited a different trend, with both high WC and BMI associated with lower-grade tumors. Our findings indicate that WC and BMI are not interchangeable obesity metrics. Further evaluation of RCC-specific outcomes using WC vs. BMI is warranted to better understand the complex relationship between general vs. abdominal obesity and RCC characteristics.
Authors: Caroline S Fox; Nancy L Heard-Costa; Peter W F Wilson; Daniel Levy; Ralph B D'Agostino; Larry D Atwood Journal: Diabetes Date: 2004-05 Impact factor: 9.461
Authors: Alexandru Ciudin; Rafael Salvador; Alex Budoy; Andreea Ciudin; Cristina Spinu; Mihai Gabriel Diaconu; Vlad Constantin; Javier Sánchez; Carlos Nicolau; Antonio Alcaraz Journal: Endocrinol Nutr Date: 2013-12-15
Authors: Alexander Kutikov; Marc C Smaldone; Brian L Egleston; Brandon J Manley; Daniel J Canter; Jay Simhan; Stephen A Boorjian; Rosalia Viterbo; David Y T Chen; Richard E Greenberg; Robert G Uzzo Journal: Eur Urol Date: 2011-04-01 Impact factor: 20.096
Authors: Juan C Camacho; Nima Kokabi; Minzhi Xing; Viraj A Master; John G Pattaras; Pardeep K Mittal; Hyun S Kim Journal: J Vasc Interv Radiol Date: 2015-03-11 Impact factor: 3.464
Authors: A Ari Hakimi; Helena Furberg; Emily C Zabor; Anders Jacobsen; Nikolaus Schultz; Giovanni Ciriello; Nina Mikklineni; Brandon Fiegoli; Philip H Kim; Martin H Voss; Hui Shen; Peter W Laird; Chris Sander; Victor E Reuter; Robert J Motzer; James J Hsieh; Paul Russo Journal: J Natl Cancer Inst Date: 2013-11-27 Impact factor: 13.506
Authors: Caroline S Fox; Nancy Heard-Costa; L Adrienne Cupples; Josée Dupuis; Ramachandran S Vasan; Larry D Atwood Journal: BMC Med Genet Date: 2007-09-19 Impact factor: 2.103